Pharma-Related, Other Big Issues Stall Final TPP Agreement
This article was originally published in PharmAsia News
Executive Summary
Pharmaceutical patent protection, intellectual property issues and state-owned businesses, all important issues to the drug industry, remained unsettled at the end of the latest round of Trans-Pacific Partnership sessions.